Literature DB >> 24548552

Pathways to poor anticoagulation control.

Z Razouki1, A Ozonoff, S Zhao, A J Rose.   

Abstract

BACKGROUND: While a considerable amount is known about which patient-level factors predict poor anticoagulation control with warfarin, measured by percent time in therapeutic range (TTR), less is known about predictors of time above or below target.
OBJECTIVE: To identify predictors of different patterns of international normalized ratio (INR) values that account for poor control, including 'erratic' patterns, where more time is spent both above and below INR target, and unidirectional patterns, where time out of range is predominantly in one direction (low or high).
METHODS: We studied 103 897 patients receiving warfarin with a target INR of 2-3 from 100 Veterans Health Administration sites between October 2006 and September 2008. Our outcomes were percent time above and below the target range. Predictors included patients' demographics, comorbidities, and other clinical data.
RESULTS: Predictors of erratic patterns included alcohol abuse (5.2% more time below and 3.7% more time above, P < 0.001 for all results), taking > 16 medications (4.6% more time below and 1.8% more time above compared to taking seven or fewer medications), and four or more hospitalizations during the study (6.6% more time below and 2% more time above compared to no hospitalization). In contrast, predictors like cancer, non-alcohol drug abuse, dementia, and bipolar disorder were associated with more time below the target range (3.4%, 5.2%, 2.6%, and 3.2%, respectively) and less (or similar) time above range.
CONCLUSION: Different patient-level factors predicted unidirectional below-target and 'erratic' patterns of INR control. Distinct interventions are necessary to address these two separate pathways to poor anticoagulation.
© 2014 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  anticoagulants; international normalized ratio; quality of healthcare; veterans; warfarin

Mesh:

Substances:

Year:  2014        PMID: 24548552     DOI: 10.1111/jth.12530

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  8 in total

1.  Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study.

Authors:  Sylvie Perreault; Payman Shahabi; Robert Côté; Stéphanie Dumas; Étienne Rouleau-Mailloux; Yassamin Feroz Zada; Sylvie Provost; Ian Mongrain; Marc Dorais; Thao Huynh; Simon Kouz; Ariel Diaz; Mark Blostein; Simon de Denus; Jacques Turgeon; Jeffrey Ginsberg; Jacques Lelorier; Lyne Lalonde; Lambert Busque; Jeannine Kassis; Mario Talajic; Jean-Claude Tardif; Marie-Pierre Dubé
Journal:  Clin Cardiol       Date:  2018-05-15       Impact factor: 2.882

2.  Time in therapeutic range: Warfarin anticoagulation for atrial fibrillation in a community-based practice.

Authors:  Derek Gateman; Melissa Elizabeth Trojnar; Gina Agarwal
Journal:  Can Fam Physician       Date:  2017-10       Impact factor: 3.275

3.  Impact of age on long-term anticoagulation and how gender and monitoring setting affect it: implications for decision making and patient management.

Authors:  Salah Abohelaika; Hilary Wynne; Peter Avery; Brian Robinson; Patrick Kesteven; Farhad Kamali
Journal:  Br J Clin Pharmacol       Date:  2016-07-24       Impact factor: 4.335

4.  Educational Level, Anticoagulation Quality, and Clinical Outcomes in Elderly Patients with Acute Venous Thromboembolism: A Prospective Cohort Study.

Authors:  Eveline Hofmann; Nicolas Faller; Andreas Limacher; Marie Méan; Tobias Tritschler; Nicolas Rodondi; Drahomir Aujesky
Journal:  PLoS One       Date:  2016-09-08       Impact factor: 3.240

Review 5.  Potential Candidates for Biomarkers in Bipolar Disorder: A Proteomic Approach through Systems Biology.

Authors:  Paola Rampelotto Ziani; Jacson Gabriel Feiten; Jéferson Ferraz Goularte; Rafael Colombo; Bárbara Antqueviezc; Luiza Paul Géa; Adriane Ribeiro Rosa
Journal:  Clin Psychopharmacol Neurosci       Date:  2022-05-31       Impact factor: 3.731

Review 6.  Social determinants of atrial fibrillation.

Authors:  Utibe R Essien; Jelena Kornej; Amber E Johnson; Lucy B Schulson; Emelia J Benjamin; Jared W Magnani
Journal:  Nat Rev Cardiol       Date:  2021-06-02       Impact factor: 32.419

7.  Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation.

Authors:  Brent A Williams; Michael A Evans; Ashley M Honushefsky; Peter B Berger
Journal:  J Am Heart Assoc       Date:  2017-10-12       Impact factor: 5.501

8.  Quality of anticoagulation with warfarin in rural Chhattisgarh, India.

Authors:  Puja Chebrolu; Sushil Patil; Timothy S Laux; Noor Al-Hammadi; Yogesh Jain; Brian Gage
Journal:  Indian J Med Res       Date:  2020-09       Impact factor: 2.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.